Lipodystrophy & Metabolic Complications: Research: 2002
- Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Cost-Effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults (November 25, 2002)
A study asserts that, generally speaking, the risks of lipodystrophy and heart disease are outweighed by the benefits of early HIV treatment.
In Archives of Internal Medicine
- National Institutes of Health Awards $1.95 Million to Study New Treatments for Drug Side Effects (November 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Metabolic Toxicities and HIV (November/December 2002)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Study Reports Self-Image Concerns in HIV-Positive People With Lipodystrophy (October 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Insulin Resistance and HIV-Related Lipoatrophy (October 9, 2002)
Dr. Nasser Mikhail attempts to explain recent study findings.
In Journal of the American Medical Association
- HIV Positive May Risk Death to Avoid Side Effect of Meds (October 2, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- The Case Against Zerit (October 2002)
Research increasingly points to NRTIs -- particularly d4T -- as a likely culprit in metabolic disorders.
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
- Overview of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- The Viramune Hepatic Safety Project: Analysis of Symptomatic Hepatic Events (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Twelve Weeks of Atazanavir Treatment Reverses Nelfinavir-Associated Hyperlipidemia: Results From BMS AI424-044 (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- The Mechanisms of Lipodystrophy: Leptin, Lipodystrophy and Insulin Resistance; Treatment of Non-HIV Lipodystrophy With Thiazolidinediones and Leptin (September 23, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Cancer Drug for Male Breast Enlargement? (September 18, 2002)
From Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- Lactic Acidosis: Watching and Waiting (September 2002)
Metformin (glucophage), used to treat diabetes, may add to the lactic acidosis risk posed by some antiretrovirals.
In HIV Treatment ALERTS!, from The Center for AIDS
- Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
|
Advertisement
|
Email
Glossary
